A Fruitful Career
Dr. Bruce Johnson first started his research on gene therapy with the National Cancer Institute (NCI) in the 1980s. Later, he served as head of the NCI’s Lung Cancer Biology section. He held this position until he joined Harvard’s Dana-Farber Cancer Institute as Chief Clinical Research Officer.
Dr. Johnson has worked in the laboratory studying lung cancer with some of the brightest researchers in the field, including Pasi Jänne, PhD., who hopes that further research could eventually make gene therapy a leading treatment for lung cancer and other asbestos-related diseases.
Dr. Bruce Johnson provides multidisciplinary care and considers demographics like age and gender when caring for each patient.
Dr. Bruce Johnson has also studied patient response to particular therapies. For example, one of his studies looked at how females who had adenocarcinoma but did not smoke had a favorable response to Erlotinib and Gefitinib.
Hopes for the Future
Dr. Johnson is a member of the External Scientific Committee and has built a foundation of research for his clinical treatment of patients. He hopes his genomics research will provide patients with better therapies.
Dr. Johnson strives to implement a multidisciplinary approach and consider demographics like age and gender when caring for each patient to provide his patients with the best care.